CD8A and neoplasm: Compared with mice receiving mpJX alone, metastases were 55% less numerous and 56% smaller and metastasis burden was 73% less 10 days after mpJX+aPD1 (Figures 8D–8F; Table S3), consistent with larger effects of mpJX+aPD1 on CD8+ cell influx, tumor cell apoptosis, and suppression of proliferation (Figure 7F; Table S1).